Epizyme announces publication of preclinical data for EPZ-6438 Epizyme announced the publication of data from preclinical studies of the company's clinical candidate EPZ-6438, a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase. Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma, implicating EZH2 as a therapeutic target in these patients. Detailed characterization of the correlation between EZH2 inhibition, methylation of the EZH2 target (H3K27), reversal of lymphomagenic gene expression and antiproliferative effects specific to EZH2 mutant-bearing NHL cell lines. Sustained tumor growth inhibition in animal models of EZH2 mutant-bearing NHL, including durable effects after drug dosing is discontinued.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.